Renephra Limited - Period Ending 2017-02-28

Renephra Limited - Period Ending 2017-02-28


Renephra Limited 06815501 false 2016-03-01 2017-02-28 2017-02-28 The principal activity of the company is medical research Digita Accounts Production Advanced 6.20.8420.1 Software true 06815501 2016-03-01 2017-02-28 06815501 2017-02-28 06815501 core:RetainedEarningsAccumulatedLosses 2017-02-28 06815501 core:ShareCapital 2017-02-28 06815501 core:SharePremium 2017-02-28 06815501 core:CurrentFinancialInstruments core:WithinOneYear 2017-02-28 06815501 bus:SmallEntities 2016-03-01 2017-02-28 06815501 bus:AuditExemptWithAccountantsReport 2016-03-01 2017-02-28 06815501 bus:AbridgedAccounts 2016-03-01 2017-02-28 06815501 bus:RegisteredOffice 2016-03-01 2017-02-28 06815501 bus:Director1 2016-03-01 2017-02-28 06815501 bus:Director2 2016-03-01 2017-02-28 06815501 bus:Director3 2016-03-01 2017-02-28 06815501 bus:Director4 2016-03-01 2017-02-28 06815501 bus:Director5 2016-03-01 2017-02-28 06815501 bus:Director6 2016-03-01 2017-02-28 06815501 bus:PrivateLimitedCompanyLtd 2016-03-01 2017-02-28 06815501 core:PatentsTrademarksLicencesConcessionsSimilar 2016-03-01 2017-02-28 06815501 countries:AllCountries 2016-03-01 2017-02-28 06815501 2016-02-29 06815501 2015-03-01 2016-02-29 06815501 2016-02-29 06815501 core:RetainedEarningsAccumulatedLosses 2016-02-29 06815501 core:ShareCapital 2016-02-29 06815501 core:SharePremium 2016-02-29 06815501 core:CurrentFinancialInstruments core:WithinOneYear 2016-02-29 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 06815501

Renephra Limited

Annual Report and Unaudited Abridged Financial Statements

for the Year Ended 28 February 2017

 

Renephra Limited

Contents

Company Information

1

Abridged Balance Sheet

2 to 3

Notes to the Abridged Financial Statements

4 to 6

 

Renephra Limited

Company Information

Directors

Mr Paul Ernest Charles Brenchley

Dr Idalia Lucja Dawidowska

Mr Alistair Taylor

Mr Savvas Ioannou Neophytou

Mr Mark Dieter Rahn

Mr Sandip Mitra

Registered office

Medtech Centre Greenheys
Manchester Science Park
Pencroft Way
Manchester
M15 6JJ

 

Renephra Limited

(Registration number: 06815501)
Abridged Balance Sheet as at 28 February 2017

Note

2017
£

2016
£

Fixed assets

 

Intangible assets

4

69,726

69,726

Current assets

 

Debtors

5,853

3,724

Cash at bank and in hand

 

21,098

10,730

 

26,951

14,454

Prepayments and accrued income

 

1,573

1,359

Creditors: Amounts falling due within one year

(16,311)

(588,509)

Net current assets/(liabilities)

 

12,213

(572,696)

Total assets less current liabilities

 

81,939

(502,970)

Accruals and deferred income

 

(27,918)

(146,234)

Net assets/(liabilities)

 

54,021

(649,204)

Capital and reserves

 

Called up share capital

2,397

246

Share premium reserve

1,995,768

1,143,967

Profit and loss account

(1,944,144)

(1,793,417)

Total equity

 

54,021

(649,204)

For the financial year ending 28 February 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

 

Renephra Limited

(Registration number: 06815501)
Abridged Balance Sheet as at 28 February 2017

Approved and authorised by the Board on 14 July 2017 and signed on its behalf by:
 

.........................................

Dr Idalia Lucja Dawidowska

Director

 

Renephra Limited

Notes to the Abridged Financial Statements for the Year Ended 28 February 2017

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Medtech Centre Greenheys
Manchester Science Park
Pencroft Way
Manchester
M15 6JJ

These financial statements were authorised for issue by the Board on 14 July 2017.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Renephra Limited

Notes to the Abridged Financial Statements for the Year Ended 28 February 2017

Intangible assets

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

At cost, with impairment reviewed

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2016 - 2).

 

Renephra Limited

Notes to the Abridged Financial Statements for the Year Ended 28 February 2017

4

Intangible assets

Total
£

Cost or valuation

At 1 March 2016

69,726

At 28 February 2017

69,726

Amortisation

Carrying amount

At 28 February 2017

69,726

At 29 February 2016

69,726

The aggregate amount of research and development expenditure recognised as an expense during the period is £Nil (2016 - £Nil).
 

5

Share capital

Allotted, called up and fully paid shares

 

2017

2016

 

No.

£

No.

£

Ordinary of £0.01 each

11,577

115.77

11,577

115.77

Ordinary A of £0.01 each

228,163

2,281.63

13,035

130.35

 

239,740

2,397

24,612

246